collection
https://read.qxmd.com/read/27733943/updates-in-anca-associated-vasculitis
#1
REVIEW
Christian Pagnoux
Antineutrophil cytoplasm antibody (ANCA)-associated vasculitides are small-vessel vasculitides that include granulomatosis with polyangiitis (formerly Wegener's granulomatosis), microscopic polyangiitis, and eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome). Renal-limited ANCA-associated vasculitides can be considered the fourth entity. Despite their rarity and still unknown cause(s), research pertaining to ANCA-associated vasculitides has been very active over the past decades. The pathogenic role of antimyeloperoxidase ANCA (MPO-ANCA) has been supported using several animal models, but that of antiproteinase 3 ANCA (PR3-ANCA) has not been as strongly demonstrated...
September 2016: European Journal of Rheumatology
https://read.qxmd.com/read/26597492/nailfold-capillaroscopic-findings-in-primary-sj%C3%A3-gren-s-syndrome-with-and-without-raynaud-s-phenomenon-and-or-positive-anti-ssa-ro-and-anti-ssb-la-antibodies
#2
MULTICENTER STUDY
Hèctor Corominas, Vera Ortiz-Santamaría, Iván Castellví, Mireia Moreno, Rosa Morlà, Teresa Clavaguera, Alba Erra, Silvia Martínez-Pardo, Sergi Ordóñez, Pilar Santo, Patricia Reyner, Maria José González, Oriol Codina, Mario Saul Gelman, Xavier Juanola-Roura, Alex Olivé, Vicenç Torrente-Segarra
The aim of this study was to assess nailfold capillaroscopic (NC) findings in patients with primary Sjögren's syndrome (PSS) with and without Raynaud's phenomenon (RP) as well as in the presence of positive anti-SSA/Ro and anti-SSB/La antibodies. Videocapillaroscopy was performed in 150 patients with PSS. Data collected included demographics, presence of RP, PSS symptoms, antinuclear antibodies, rheumatoid factor, anti-Ro, anti-La, anti-CCP, salivary scintigraphy, labial biopsy, and NC findings. RP was present in 32% of PSS, keratoconjunctivitis sicca in 91%, oral xerosis in 93%, and skin or genital xerosis in 53%...
March 2016: Rheumatology International
https://read.qxmd.com/read/26288663/belimumab-in-systemic-lupus-erythematosus-a-perspective-review
#3
REVIEW
Joyce S Hui-Yuen, Xiao Q Li, Anca D Askanase
Belimumab (Benlysta(®)) is a fully humanized monoclonal antibody that inhibits B-lymphocyte stimulator (also known as B cell activating factor of the tumor necrosis factor family) and was approved by the US Food and Drug Administration and the European Medicines Evaluation Agency for treatment of autoantibody-positive systemic lupus erythematosus (SLE) in adults. This review discusses the key findings of the phase III trials, post hoc analyses, and real-world postmarketing use of belimumab in the routine care of SLE patients...
August 2015: Therapeutic Advances in Musculoskeletal Disease
https://read.qxmd.com/read/26075287/uniphasic-blanching-of-the-fingers-abnormal-capillaroscopy-in-nonsymptomatic-digits-and-autoantibodies-expanding-options-to-increase-the-level-of-suspicion-of-connective-tissue-diseases-beyond-the-classification-of-raynaud-s-phenomenon
#4
JOURNAL ARTICLE
Francesca Ingegnoli, Roberta Gualtierotti, Annalisa Orenti, Tommaso Schioppo, Giovanni Marfia, Rolando Campanella, Claudio Mastaglio, Pier Luigi Meroni, Patrizia Boracchi
In patients with Raynaud's phenomenon (RP), the role of medical history, capillaroscopy, and autoantibodies in order to provide an early diagnosis of connective tissue disease (CTD) were examined. 115 consecutive adults with uni-, bi-, or triphasic colour changes of the fingers were studied. RP was bilateral in 92.7% of patients. The middle finger was significantly more affected. A lack of association between fingers affected by RP and fingers with capillary abnormalities was observed OR = 0.75 (0.34-1.66)...
2015: Journal of Immunology Research
https://read.qxmd.com/read/25889905/application-of-the-2013-acr-eular-classification-criteria-for-systemic-sclerosis-to-patients-with-raynaud-s-phenomenon
#5
JOURNAL ARTICLE
Jin-Su Park, Min-Chan Park, Jason Jungsik Song, Yong-Beom Park, Soo-Kon Lee, Sang-Won Lee
INTRODUCTION: We investigated how many patients, who presented with Raynaud's phenomenon (RP) and who had not been classified as systemic sclerosis (SSc), would be reclassified as SSc, if the 2013 American College of Rheumatology (ACR)/the European League Against Rheumatism (EULAR) classification criteria were used. We also analyzed the predictive values of the reclassification as SSc in those patients. METHODS: We consecutively enrolled 64 patients with RP and 60 patients with SSc...
March 22, 2015: Arthritis Research & Therapy
https://read.qxmd.com/read/25940537/rivaroxaban-in-antiphospholipid-syndrome-raps-protocol-a-prospective-randomized-controlled-phase-ii-iii-clinical-trial-of-rivaroxaban-versus-warfarin-in-patients-with-thrombotic-antiphospholipid-syndrome-with-or-without-sle
#6
RANDOMIZED CONTROLLED TRIAL
H Cohen, C J Doré, S Clawson, B J Hunt, D Isenberg, M Khamashta, N Muirhead
INTRODUCTION: The current mainstay of the treatment of thrombotic antiphospholipid syndrome (APS) is long-term anticoagulation with vitamin K antagonists (VKAs) such as warfarin. Non-VKA oral anticoagulants (NOACs), which include rivaroxaban, have been shown to be effective and safe compared with warfarin for the treatment of venous thromboembolism (VTE) in major phase III prospective, randomized controlled trials (RCTs), but the results may not be directly generalizable to patients with APS...
September 2015: Lupus
1
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.